Literature DB >> 16896313

Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles.

Sandrine Rorive1, Calliope Maris, Olivier Debeir, Flavienne Sandras, Michel Vidaud, Ivan Bièche, Isabelle Salmon, Christine Decaestecker.   

Abstract

Although World Health Organization (WHO) grade I pilocytic astrocytomas and grade II diffuse astrocytomas have been classified for decades as different clinicopathologic entities, few, if any, data are available on the biologic features explaining these differences. Although more than 50 microarray-related studies have been carried out to characterize the molecular profiles of astrocytic tumors, we have identified only 11 that provide sound data on low-grade astrocytomas. We have incorporated these data into a comparative analysis for the purpose of identifying the most relevant molecular markers characterizing grade I pilocytic and grade II diffuse astrocytomas. Our analysis has identified various interesting genes that are differentially expressed in either grade I or grade II astrocytomas when compared with normal tissue and/or high-grade (WHO grade III and IV) astrocytomas. A large majority of these genes encode adhesion, extracellular matrix, and invasion-related proteins. Interestingly, a group of 6 genes (TIMP4, C1NH, CHAD, THBS4, IGFBP2, and TLE2) constitute an expression profile characteristic of grade I astrocytomas as compared with all other categories of tissue (normal brain, grade II, and high-grade astrocytomas). The end products (proteins) of these genes act as antimigratory compounds, a fact that could explain why pilocytic astrocytomas behave as compact (well-circumscribed) tumors as opposed to all the other astrocytic tumor types that diffusely invade the brain parenchyma. Having validated these molecular markers by means of real-time reverse transcriptase-polymerase chain reaction, an integrated model was proposed illustrating how and why pilocytic astrocytomas constitute a distinct biologic and pathologic entity when compared with diffuse astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896313     DOI: 10.1097/01.jnen.0000228203.12292.a1

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  18 in total

1.  Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice.

Authors:  Fanny Burel-Vandenbos; Laurent Turchi; Maxime Benchetrit; Eric Fontas; Zoe Pedeutour; Valérie Rigau; Fabien Almairac; Damien Ambrosetti; Jean-François Michiels; Thierry Virolle
Journal:  Neuro Oncol       Date:  2013-08-09       Impact factor: 12.300

2.  Increased β-catenin/Tcf signaling in pilocytic astrocytomas: a comparative study to distinguish pilocytic astrocytomas from low-grade diffuse astrocytomas.

Authors:  Gangadhara Reddy Sareddy; Khamushavalli Geeviman; Manas Panigrahi; Sundaram Challa; Anita Mahadevan; Phanithi Prakash Babu
Journal:  Neurochem Res       Date:  2011-09-16       Impact factor: 3.996

3.  Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms.

Authors:  Anne-Laure Trépant; Christelle Bouchart; Sandrine Rorive; Sébastien Sauvage; Christine Decaestecker; Pieter Demetter; Isabelle Salmon
Journal:  Tumour Biol       Date:  2014-11-12

Review 4.  Pathological and molecular advances in pediatric low-grade astrocytoma.

Authors:  Fausto J Rodriguez; Kah Suan Lim; Daniel Bowers; Charles G Eberhart
Journal:  Annu Rev Pathol       Date:  2012-10-29       Impact factor: 23.472

5.  Nitroproteins in Human Astrocytomas Discovered by Gel Electrophoresis and Tandem Mass Spectrometry.

Authors:  Fang Peng; Jianglin Li; Tianyao Guo; Haiyan Yang; Maoyu Li; Shushan Sang; Xuejun Li; Dominic M Desiderio; Xianquan Zhan
Journal:  J Am Soc Mass Spectrom       Date:  2015-10-08       Impact factor: 3.109

6.  BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.

Authors:  Stefan Pfister; Wibke G Janzarik; Marc Remke; Aurélie Ernst; Wiebke Werft; Natalia Becker; Grischa Toedt; Andrea Wittmann; Christian Kratz; Heike Olbrich; Rezvan Ahmadi; Barbara Thieme; Stefan Joos; Bernhard Radlwimmer; Andreas Kulozik; Torsten Pietsch; Christel Herold-Mende; Astrid Gnekow; Guido Reifenberger; Andrey Korshunov; Wolfram Scheurlen; Heymut Omran; Peter Lichter
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

7.  Three meta-analyses define a set of commonly overexpressed genes from microarray datasets on astrocytomas.

Authors:  Zhongyu Liu; Mengyu Xie; Zhiqiang Yao; Yulong Niu; Youquan Bu; Chunfang Gao
Journal:  Mol Neurobiol       Date:  2012-11-08       Impact factor: 5.590

Review 8.  Systematic review of protein biomarkers of invasive behavior in glioblastoma.

Authors:  Eli T Sayegh; Gurvinder Kaur; Orin Bloch; Andrew T Parsa
Journal:  Mol Neurobiol       Date:  2013-11-24       Impact factor: 5.590

9.  Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival.

Authors:  Farshid Dayyani; Jianfeng Wang; Jing-Ruey J Yeh; Eun-Young Ahn; Erica Tobey; Dong-Er Zhang; Irwin D Bernstein; Randall T Peterson; David A Sweetser
Journal:  Blood       Date:  2008-02-07       Impact factor: 22.113

10.  Deregulation of ion channel and transporter encoding genes in pediatric gliomas.

Authors:  Marika Masselli; Pasquale Laise; Giulia Tonini; Duccio Fanelli; Serena Pillozzi; Valentina Cetica; Martina Da Ros; Iacopo Sardi; Anna Maria Buccoliero; Maurizio Aricò; Lorenzo Genitori; Andrea Becchetti; Annarosa Arcangeli
Journal:  Front Oncol       Date:  2012-05-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.